Immutep is listed on the Australian Stock Exchange (ASX:IMM) and on the NASDAQ Global Market (NASDAQ:IMMP) in the U.S. (ADR's).
We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.
We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.
Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.
Latest Media Releases
Latest News
Interviews /
by Peter Milios -
A month ago
23 Sep 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the company's latest results in head and neck cancer.
Interviews /
by Peter Milios -
2 months ago
19 Aug 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of aut…
Interviews /
by Manny Anton -
3 months ago
30 Jul 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and nec…
Company News /
by Peter Milios -
3 months ago
22 Jul 2024 - Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer…
Company News /
by Abbey Phillipps -
6 months ago
18 Apr 2024 - A snapshot of the stocks on the move, featuring Nimy Resources, New Age Exploration and Immutep.
Interviews /
by Manny Anton -
7 months ago
25 Mar 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck …
Company News /
by Abbey Phillipps -
A year ago
09 Nov 2023 - A snapshot of the stocks on the move, featuring Sunstone Metals (ASX:STM), Immutep (ASX:IMM, NASDAQ:IMMP), European Metals Holdings (ASX:EMH & AIM:EMH) and QX Resourc…
Interviews /
by Paul Sanger -
A year ago
31 Oct 2023 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Co…
Company News /
by Abbey Phillipps -
A year ago
23 Oct 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM; NASDAQ:IMMP), Chimeric Therapeutics (ASX:CHM) and Sayona Mining (ASX:SYA; OTCQB:SYAXF).